Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2019-09-12 Board/Management Inform…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Scientific Advisory Board Appointment 2 pages 142.6KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 13 September 2019 about the appointment of Dr. Fred K Chen to the Scientific Advisory Board and the founding of a Clinical Advisory Board. It focuses on management and advisory board changes and does not contain financial data, regulatory certifications, or report publication notices. The content is about a senior advisory appointment, which fits the category of Board/Management Information (MANG). The document length is 4623 characters, which is sufficient for a full announcement rather than a brief notice. There is no indication that this is a report or a report publication announcement. Therefore, the appropriate classification is MANG with high confidence.
2019-09-12 English
Investor Relations Presentation 12 pages 1.5MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Relations Presentation September 2019' and contains detailed slides about PYC Therapeutics' technology, competitive advantages, scientific team, and business strategy. It is structured as a presentation aimed at investors, focusing on the company's platform, market opportunity, milestones, and team. There are no financial statements, regulatory certifications, or voting results. The content is typical of an investor presentation rather than a formal report or announcement. The length (8609 characters) and content confirm it is a presentation document rather than a brief announcement or regulatory filing. Therefore, the appropriate classification is Investor Presentation (IP).
2019-09-03 English
Successful Competitive Drug Evaluation in Animals 4 pages 324.7KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement dated 3 September 2019 from Phylogica Limited (PYC Therapeutics) describing successful pre-clinical drug evaluation results in animals. It focuses on scientific and technical data about drug delivery technology and its effectiveness in animal models. There is no indication that this is a full financial report, audit report, earnings release, or regulatory filing. It is a corporate announcement about research progress and competitive evaluation results, typical of a Capital/Financing Update or general corporate update. However, since it does not discuss fundraising, capital structure changes, or financing activities, it does not fit the Capital/Financing Update category. It is also not a regulatory filing or report publication announcement. The document is a scientific and technical update on drug development progress, which is best classified under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2019-09-02 English
Preliminary Final Report 16 pages 311.6KB
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E Preliminary Final Report Year ended 30 June 2019' and contains detailed financial statements including profit and loss, financial position, cash flows, and notes to the financial statements. It also includes directors' commentary, operating results, corporate updates, and detailed financial data for the full fiscal year ending 30 June 2019. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of comprehensive financial statements and notes confirms this is a full annual financial report. Appendix 4E is a common Australian Securities Exchange (ASX) form used for preliminary final reports, which are annual reports. Therefore, this document fits the definition of an Annual Report (10-K equivalent). FY 2019
2019-08-29 English
Investor Call 2 pages 100.4KB
Investor Presentation Classification · 90% confidence The document is an announcement about an upcoming investor call scheduled for 4 September 2019, hosted by Phylogica Limited (PYC Therapeutics). It invites shareholders to register and submit questions for the call. The content is focused on providing logistical details for the call and a brief company overview, with no financial data, results, or detailed discussion of financial performance. The document length is short (2851 characters) and it does not contain a transcript or detailed financial report. Therefore, it is not a Call Transcript (CT) but rather an announcement about the call. Given the nature of the content, it fits best as an Investor Presentation (IP) or possibly a Regulatory Filing (RNS). However, since it is specifically about an investor call event and includes registration details, the best fit is Investor Presentation (IP). Confidence is high due to clear indicators of an investor call announcement and absence of financial data or transcript.
2019-08-22 English
Successful Time - Course Studies in Animals 3 pages 111.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 22 August 2019 from Phylogica Limited (PYC Therapeutics) describing successful preclinical study results of their drug delivery technology in animals. It highlights scientific and technical results of a time-course study in mice, focusing on drug efficacy and dosing profile. The document is relatively short (4600 characters) and is an announcement of study results rather than a full financial or regulatory report. There is no indication of financial statements, regulatory certifications, voting results, or management changes. It is a typical corporate announcement of scientific progress aimed at investors and the market. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2019-08-21 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.